Therapeutic | Ramucirumab |
Target | KDR |
Heavy Chain | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS |
Light Chain | DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK |
100% seqID Fv Structure | 3s34 [Fvs: HL], 3s36 [Fvs: HL], 3s37 [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 3s34 [Fvs: HL] |
100% seqID Structure | 3s37 [Fvs: HL] |
100% seqID Structure | 3s36 [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (Aug '22) | Approved |
Estimated Status (Aug '22) | Active |
Recorded Developmental Technology | Dyax Human Phage Display |
INN Year Proposed | 2008 |
INN Year Recommended | 2009 |
Companies Involved | Dyax, AstraZeneca, Dana-Farber Cancer Institute, Eli Lilly, Merck Sharp & Dohme, University of Texas M. D. Anderson Cancer Center, Washington University School of Medicine |
Conditions Approved | Colorectal cancer, Gastric cancer, Non-small cell lung cancer, Liver cancer |
Conditions Active | Oesophageal cancer, Urogenital cancer, Biliary cancer, Carcinoid tumour, Solid tumours, Pancreatic cancer |
Conditions Discontinued | Breast cancer, Malignant melanoma, Ovarian cancer, Prostate cancer, Renal cell carcinoma |
Notes |
SAbDab papers
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]
Thera-SAbDab paper
Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]